Developments in preclinical AIDS vaccine efficacy models

AIDS

Volumn 14, Issue SUPPL. 3, 2000, Pages

  Bogers, W M J M ^a   Cheng Mayer, C ^a   Montelaro, R C ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

AIDS vaccines; Animal models; EIAV; FIV; HIV 1; Immune correlates; Mucosal immunity; SHIV; SIV

Indexed keywords

ANTIRETROVIRUS AGENT; DNA VACCINE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 140; HUMAN IMMUNODEFICIENCY VIRUS IMMMUNOGLOBULIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN; INACTIVATED VIRUS VACCINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2 F 5; MONOCLONAL ANTIBODY 2 G 12; RNA DIRECTED DNA POLYMERASE INHIBITOR; SIMIAN HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; DRUG EFFICACY; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOPROPHYLAXIS; IMMUNOTHERAPY; INFECTION PREVENTION; MODEL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION; VIRUS STRAIN;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; ANIMALS; CATS; DISEASE MODELS, ANIMAL; DRUG DESIGN; HIV; HUMANS; IMMUNITY, MUCOSAL; IMMUNODEFICIENCY VIRUS, FELINE; INFECTIOUS ANEMIA VIRUS, EQUINE; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 0033778034     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (102)

1. Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors
2. Infection of baboons with simian/human immunodeficlency viruses
3. Comparison of in vitro and in vivo infectivity of different clade B HIV-1 envelope chimeric simian/human immunodeficiency viruses in Macaca mulatta
4. Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins
5. Persistent infection of macaques with simian-human immunodeficiency viruses
6. Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses (SHIV)
7. The construdion and evaluation of SIV/HIV chimeras that express the envelope of European HIV type 1 isolates
8. An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys
9. Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs
10. Chimeric simian/human immunodeficiency virus that causes progressive loss of CD4+ T cells and AIDS in pig-tailed macaques
11. Rhesus macaques that become systemically infected with pathogenic SHIV 89.6-PD after intravenous, rectal, or vaginal inoculation and fall to make an antiviral antibody response rapidly develop AIDS
12. Fatal immunopathogenesis by SIV/HIV-1 (SHIV) containing a variant form of the HIV-1SF33 env gene in juvenile and newborn rhesus macaques
13. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys
14. Infection and pathogenicity of chimeric simian-human immunodeficiency viruses in macaques: Determinants of high virus loads and CD4 killing
15. Progress in the development of an HIV-1 vaccine
16. Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease
17. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS
18. Exclusive and persistent use of the entry coreceptor CXCR4 by HIV-1 from a subject homozygous for CCR D32
19. Infection of rhesus macaques with a simian-human immunodeficiency virus (SHIV) containing a HIV-1 subtpe-E envelope gene
20. Establishment of a SHIV/macaque model using an R5-tropic HIV-1 subtype C envelope
21. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine
22. Modified vaccinia virus ankara (MVA) vectors: Immunization and SHIV challenge studies
23. HIV-1 vaccine-induced immune responses which correlate with protection from SHIV infection: Compiled preclinical efficacy data from trials with ten different HIV-1 vaccine candidates
24. Oral immunization of macaques with attenuated vaccine virus induces protection against vaginally transmitted
25. Limited protection from a pathogenic chimeric simian-human immunodeficiency virus challenge following immunization with attenuated simian immunodeficiency virus
26. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations
27. Protection of macaques against a SHIV with a homologous HIV-1 Env and a pathogenic SHIV-89.6P with a heterologous Env by vaccination with multiple gene-deleted SHIVs
28. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection
29. Neutralizing antibodies administered before, but not after, virulent SHIV prevent infection in macaques
30. Passively administered neutralizing serum that protected macaques against infection with parenterally inoculated pathogenic simian-human immunodeficiency virus failed to protect against mucosally inoculated virus
31. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies
32. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
33. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys
34. Immunization with live attenuated simian immunodeficiency virus induces strong type 1 T helper responses and beta-chemokine production
35. A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals
36. Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex
37. Low frequency HIV-1 envelope epitope-specific CD4+ T lymphocyte responses on SHIV-infected and vaccinated rhesus monkeys detected using a peptide/MHC class II tetramer
38. AIDS preclinical vaccine development: Biennial survey of HIV, SIV, and SHIV challenge studies in vaccinated nonhuman primates
39. Mucosal transmission of simian immunodeficiency virus
40. Mucosal immunity and tolerance: Relevance to vaccine development
41. HIV transmission and immune protection at mucosal surfaces
42. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection
43. Antibody-secreting cells specific for simian immunodeficiency virus antigens in lymphoid and mucosal tissues of immunized macaques
44. A rational basis for mucosal vaccination against HIV infection
45. Langerhans cells, macrophages and lymphocyte subsets in the cervix and vagina of rhesus macaques
46. Differential kinetics and distribution of antibodies in serum and nasal and vaginal secretions after nasal and oral vaccination of humans
47. The effect of route of immunization on mucosal immunity and protection
48. Vaccine protection by a triple deletion mutant of simian immunodeficiency virus
49. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques
50. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques
51. Macaques infected with live attenuated SIVmac are protected against super-infection via the rectal mucosa
52. Rhesus macaques previously infected with simian/human immunodeficiency virus are protected from vaginal challenge with pathogenic SIVmac239
53. Live attenuated simian immunodeficiency virus (SIV)mac in macaques can induce protection against mucosal infection with SIVsm
54. Oral immunization of macaques with attenuated vaccine virus induces protection against vaginally transmitted AIDS
55. Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: Inverse relationship of degree of protection with level of attenuation
56. Beta-chemokine production in macaques vaccinated with live attenuated virus correlates with protection against simian immunodeficiency virus (SIVsm) challenge
57. Poxvirus-based vaccine candidates for cancer, AIDS, and other infectious diseases
58. Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): Dependence on route of challenge exposure
59. An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge
60. Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251
61. Toward a poliovirus-based simian immunodeficiency virus vaccine: Correlation between genetic stability and immunogenicity
62. Mucosal immunization of cynomolgus macaques with two serotypes of live poliovirus vectors expressing simian immunodeficiency virus antigens: Stimulation of humoral, mucosal, and cellular immunity
63. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160
64. Limited breadth of the protective immunity elicited by simian immunodeficiency virus SIVmne gp160 vaccines in a combination immunization regimen
65. Protection of macaques against intrarectal infection by a combination immunization regimen with recombinant simian immunodeficiency virus SIVmne gp160 vaccines
66. Protection against vaginal SIV transmission with microencapsulated vaccine
67. Combined systemic and mucosal immunization with microsphere-encapsulated inactivated simian immunodeficiency virus elicits serum, vaginal, and tracheal antibody responses in female rhesus macaques
68. Induction of mucosal antibody responses by microsphere-encapsulated formalin-inactivated simian immunodeficiency virus in a male urethral challenge model
69. Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection
70. Protective mucosal immunity elicited by targeted lilac lymph node immunization with a subunit SIV envelope and core vaccine in macaques
71. Mucosal Th1- versus Th2-type responses for antibody- or cell-mediated immunity to simian immunodeficiency virus in rhesus macaques
72. Antiviral cytotoxic T lymphocytes in vaginal mucosa of simian immunodeficiency virus-infected rhesus macaques
73. Protection of human immunodeficiency virus type 2-exposed seronegative macaques from mucosal simian immunodeficiency virus transmission
74. Mucosal or targeted lymph node immunization of macaques with a particulate SIVp27 protein elicits virus-specific CTL in the genito-rectal mucosa and draining lymph nodes
75. Mucosal phenotype of antiviral cytotoxic T lymphocytes in the vaginal mucosa of SIV-infected rhesus macaques
76. Selective induction of protective MHC class I-restricted CTL in the intestinal lamina propria of rhesus monkeys by transient SIV infection of the colonic mucosa
77. Evaluation of antibody parameters as potential correlates of protection or enhancement by experimental vaccines to equine infectious anemia virus
78. AIDS activation studies using feline immunodeficiency virus as a model: Immunization with inactivated whole virus suppresses viremia following intravaginal challenge with infected cells but not following intravenous challenge with cell-free virus
79. Efficacy of inactivated whole virus and envelope subunit vaccines in preventing infection and disease by EIAV
80. Feline immunodeficiency virus vaccination: Characterization of the immune correlates of protection
81. Vaccination with fixed feline immunodeficiency virus (FIV) infected cells: Protection, breakthrough, and specificity of response
82. Studies of AIDS vaccination using an ex vivo feline immunodeficiency virus model: Protection conferred by a fixed-cell vaccine against cell-free and cell-associated challenge differs in duration and is not easily boosted
83. Accelerated viremia in cats vaccinated with autologous FIV-infected cells
84. Vaccination with experimental feline immunodeficiency virus vaccines, based on autologous infected cells, elicits enhancement of homologous challenge infection
85. Enhancement of EIAV replication and disease by immunization with a baculovirus-expressed recombinant envelope surface glycoprotein
86. Immunization with a recombinant envelope protein (rgp90) of EIAV produces a spectrum of vaccine efficacy ranging from a lack of clinical disease to severe enhancement
87. Enhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines
88. Enhancement of feline immunodeficiency virus (FIV) infection after DNA vaccination with the FIV envelope
89. DNA vaccination against feline retroviruses
90. AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: Detailed analysis of the humoral immune response to a protective vaccine
91. DNA vaccination affords significant protection against feline immunodeficiency virus infection without inducing detectable antiviral antibodies
92. Efficacy of prime-boost protocol: Canarypox-based feline immunodeficiency virus (FIV) vaccine and inactivated FIV-infected cell vaccine against heterologous FIV challenge in cats
93. Feline immunodeficiency virus subunit vaccines that induce virus neutralising antibodies but no protection against challenge infection
94. In vitro antibody-dependent enhancement assays are insensitive indicators of in vivo vaccine enhancement of equine infectious anemia virus
95. Evaluation of a candidate human immunodeficiency virus type 1 (HIV-1) vaccine in macaques: Effect of vaccination with HIV-1 gp 120 on subsequent challenge with heterologous simian immunodeficiency virus-HIV-1 chimeric virus
96. Relative efficiency of highly active anti-retroviral therapy initiated early after intravenous exposure of macaques to pathogenic SHIV
97. High viral replication of SHIV-RT in vivo leads to the emergence of mutants partially resistant to non-nucleosidic reverse transcriptase treatment
98. Vaginal immunization of Cynomolgus monkeys with Streptococcus gordonii expressing HIV-1 and HPV 16 antigens
99. Recombinant, attenuated Salmonella typhimurium stimulate lymphoproliferative responses to SIV capsid antigen in rhesus macaques
100. Vaccination with a feline immunodeficiency virus multiepitopic peptide induces cell-mediated and humoral immune responses in cats, but does not confer protection
101. Delayed infection after immunization with a peptide from the transmembrane glycoprotein of the feline immunodeficiency virus
102. A particulate viral protein vaccine reduces viral load and delays progression to disease in immunized ponies challenged with equine infectious anemia virus